Exclusive Summary

• - Originator launched around 1978 with patents long expired; no active blocking IP, enabling fast global market entry and tender participation.
• - Stable ICU demand: ~64 million heart-failure patients worldwide, ~0.5–1.0 million cardiogenic-shock cases annually, plus millions of dobutamine stress-echocardiography tests.
• - Included in the WHO Essential Medicines List and recommended by AHA/ACC, ESC, and Sepsis guidelines for low cardiac output/hypoperfusion—standard hospital rescue therapy.
• - US registration (SRA-compliant) facilitates reliance/abridged approvals and accelerates uptake with strong compliance credentials.
• - Mature generics but supply fluctuations exist; with two practical strengths and reliable supply, the product can win tenders and deliver ~30–70% savings vs originator.